179 related articles for article (PubMed ID: 18762711)
1. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
Choi MK; Song IS
Drug Metab Pharmacokinet; 2008; 23(4):243-53. PubMed ID: 18762711
[TBL] [Abstract][Full Text] [Related]
2. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
3. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
Zolk O
Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
[TBL] [Abstract][Full Text] [Related]
4. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
5. Organic cation transporters.
Ciarimboli G
Xenobiotica; 2008 Jul; 38(7-8):936-71. PubMed ID: 18668435
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in organic cation transporters and considerations in drug development.
Varma MVS
Expert Opin Drug Metab Toxicol; 2023 Mar; 19(3):149-164. PubMed ID: 37070463
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism in human organic cation transporters and metformin action.
Takane H; Shikata E; Otsubo K; Higuchi S; Ieiri I
Pharmacogenomics; 2008 Apr; 9(4):415-22. PubMed ID: 18384255
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Blanc Mettral J; Faller N; Cruchon S; Sottas L; Buclin T; Schild L; Choong E; Nahimana A; Decosterd LA
Drug Metab Lett; 2019; 13(2):102-110. PubMed ID: 30734690
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
10. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
11. Predicting benefit from imatinib: are we close?
Gandhi MD; Kaklamani VG
Leuk Lymphoma; 2014 Nov; 55(11):2421-2. PubMed ID: 24684225
[No Abstract] [Full Text] [Related]
12. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
13. Role of organic cation transporters in drug-drug interaction.
Koepsell H
Expert Opin Drug Metab Toxicol; 2015; 11(10):1619-33. PubMed ID: 26206523
[TBL] [Abstract][Full Text] [Related]
14. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
Di Paolo A; Polillo M; Capecchi M; Cervetti G; Baratè C; Angelini S; Guerrini F; Fontanelli G; Arici R; Ciabatti E; Grassi S; Bocci G; Hrelia P; Danesi R; Petrini M; Galimberti S
Pharmacogenomics J; 2014 Aug; 14(4):328-35. PubMed ID: 24589908
[TBL] [Abstract][Full Text] [Related]
15. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
16. Role of organic cation transporters in drug-induced toxicity.
Ciarimboli G
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):159-74. PubMed ID: 21241199
[TBL] [Abstract][Full Text] [Related]
17. Drug transporters and imatinib treatment: implications for clinical practice.
Eechoute K; Sparreboom A; Burger H; Franke RM; Schiavon G; Verweij J; Loos WJ; Wiemer EA; Mathijssen RH
Clin Cancer Res; 2011 Feb; 17(3):406-15. PubMed ID: 21163869
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
Guo D; Yang H; Li Q; Bae HJ; Obianom O; Zeng S; Su T; Polli JE; Shu Y
Pharm Res; 2018 Sep; 35(11):204. PubMed ID: 30191328
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.
Clark RE; Davies A; Pirmohamed M; Giannoudis A
Leuk Lymphoma; 2008 Apr; 49(4):639-42. PubMed ID: 18398725
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z; Duin NJCB; Jansen K; Vijverberg SJH; Maitland-van der Zee AH; Masereeuw R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
